Enrique Conterno, via Eli Lilly
January 6, 2020 08:01 AM ESTUpdated 09:40 AM
People
R&D

As ques­tions swirl around lead drug, Fi­bro­Gen (and As­traZeneca) find a new cham­pi­on from Big Phar­ma

John Carroll

Editor & Founder

Two months af­ter En­rique Con­ter­no left his high-pro­file post as the head of Lil­ly Di­a­betes and Lil­ly USA, the 27-year phar­ma vet is back in the game — this time as the new­ly ap­point­ed CEO of a close­ly-watched biotech.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times